Phio Pharmaceuticals (United States)
Phio Pharmaceuticals Corporation is a US clinical stage biotechnology company developing its INTASYL siRNA in immuno-oncology. Formerly known as RXi Pharmaceuticals, the company's name was changed to Phio Pharmaceuticals in 2018. Derived from Wikipedia licensed CC-BY-SA.
Open Access statistics for Phio Pharmaceuticals (United States), United States, covering academic research published from 2009 to 2024. Read More.
Open Access Percentage
63%
Total
Publications
60
Total Open
Publications
38
Total
Citations
898
Open Access
Percentage
63%
Total
Publications
60
Total Open
Publications
38
Total
Citations
898
Breakdown
Publisher Open
49%
Both
12%
Other Platform Open
2%
Closed
37%
Percentage of Open Access over time
Publisher Open
Both
Other Platform Open
Closed
Volume of Open Access over time
Open
Closed
Publisher Open
OA Journal 17%
6
Hybrid 50%
18
No Guarantees 33%
12
Other Platform Open
Domain 75%
6
Other Internet 25%
2
Institution 13%
1
Preprint 0%
0
Public 0%
0
Other Platform Locations
Name | Platform Type | Publications |
|---|---|---|
PubMed Central | Domain | 6 |
DOI | Other Internet | 2 |
JAMA - The Journal of the American Medical Association Network | Institution | 1 |